BC-DXI-843

BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer.


Cat. No.: EX-A4577	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
250mg	1350	In-stock
1g	Get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	2421117-98-6
Purity	>98%
Formula	C28H26N4O4S2
Mol Weight	546.66
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Aneesh Sivaraman, Dae Gyu Kim, Deepak Bhattarai, Minkyoung Kim, Hwa Young Lee, Semi Lim, Jiwon Kong, Ja-il GooSeunghwan Shim, Seungbeom Lee, Young-Ger Suh,Yongseok Choi, Sunghoon Kim, Kyeong Lee. Synthesis and Structure–Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy. J. Med. Chem. 2020. doi: 10.1021/acs.jmedchem.9b01961.
CoA	CoA of BC-DXI-843

Smiles:	COC(C=C1)=CC=C1C2=CSC(NC([C@@H](NS(C3=CC=C(C)C=C3)(=O)=O)CC4=CNC5=C4C=CC=C5)=O)=N2


		Search